News room

Egetis is an innovative and integrated pharmaceutical company, focusing on projects in late-stage development for commercialization for treatments of serious diseases with significant unmet medical needs in the orphan drug segment

PledPharma’s PledOx® safety studies positive

July 6, 2012

PledPharma AB
Company Announcement

PledPharma’s PledOx® safety studies positive

Stockholm, 2012-07-06 08:30 CEST (GLOBE NEWSWIRE) -- PledPharma (STO:PLED)
today announced positive results from its PledOx® long term pre-clinical safety
studies. No unwanted effects on vital organs were detected. The final results
have been an important part of the preparations ahead of the phase IIb PledOx
study initiation in colorectal cancer patients, and an important part of the
PledOx documentation for clinical trial applications. 

Potential effects of high intravenous doses of PledOx on vital organs (central
nervous system, cardiovascular and respiratory system) were evaluated in
pre-clinical safety studies. PledOx was given 3 times weekly for 3 months.
Total doses were up to more than 185-fold the maximal proposed clinical dose. 

No effects on blood pressure, heart rate or electrocardiogram (ECG) were
observed. The neurologic evaluations did not show any functional changes in the
central or peripheral nervous system. Finally, no effects on the respiratory
system were noted. 

“The positive results from these very important complementary long term
pre-clinical safety studies validate the use of PledOx as intended in repeated
dosing. We have previously shown that PledOx is safe in a shorter pre-clinical
safety study, and we know that the clinically used pharmaceutical it originated
from does not have clinical safety concerns”, says CEO Jacques Näsström. 

For further information please contact:

Jacques Näsström, CEO, cell: +46 73 713 0979

Erik Kinnman, Investor relations, cell: +46 73 422 1540

About PledPharma

PledPharma is a Swedish specialty pharma company that develops a new medicine,
PledOx®, for prevention of the severe side effects that patients develop as a
consequence of chemotherapy treatment of cancer. Many times the treatment
cannot be carried out as planned due to very difficult side effects. The
current market for supportive cancer care is some SEK 72 billion. PledOx is a
medicine within the patent protected substance class PLED, which protects the
body’s normal cells against oxidative stress. Oxidative stress is a condition
where an overabundance of harmful oxygen molecules (free oxygen radicals) has
been formed. We are also evaluating opportunities with PLED substances for
other diseases. PledPharma (STO:PLED) is listed on NASDAQ OMX First North. Erik
Penser Bankaktiebolag is the Certified Adviser. For more information, please



Contact us

Address: Klara Norra Kyrkogata 26, SE 111 22 Stockholm, Sweden

Phone: +46 8 679 72 10